Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial
Vincent A. Miller, Vera Hirsh, Jacques Cadranel, Yuh Min Chen, Keunchil Park, Sang We Kim, Caicun Zhou, Wu Chou Su, Mengzhao Wang, Yan Sun, Dae Seog Heo, Lucio Crino, Eng Huat Tan, Tsu Yi Chao, Mehdi Shahidi, Xiuyu Julie Cong, Robert M. Lorence, James Chih Hsin Yang
Research output: Contribution to journal › Article › peer-review
841Scopus
citations
Fingerprint
Dive into the research topics of 'Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial'. Together they form a unique fingerprint.